Patent Publication Number: US-2023151422-A1

Title: Cbx6 as epigenetic marker for the identification of immune cells, in particular memory b cells

Description:
The present invention relates to a method, in particular an in vitro method, for identifying memory B cells, comprising analyzing epigenetic modifications/properties of (including the methylation status) of at least one CpG position in the mammalian gene region for Chromobox protein homolog 6 (CBX6), wherein a demethylation or lack of methylation of said gene region is indicative for a memory B cell, when compared to a non-memory B cell. The analyses according to the invention can identify memory B cells on an epigenetic level and distinguish them from all other cells in complex samples, such as, for example, other blood or immune cells. The present invention furthermore provides an improved method for quantifying memory B cells, in particular in complex samples. The method can be performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue. 
     Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof. It is one aim of this invention to provide a novel, more robust means to quantitatively detect and measure memory B cells of the blood within any solid organs, tissue or body fluid of a mammal. 
     BACKGROUND OF THE INVENTION 
     B cells develop from hematopoietic precursor cells in an ordered maturation and selection process. Memory B cells are a B cell sub-type that are formed within germinal centers following primary infection and are important in generating an accelerated and more robust antibody-mediated immune response in the case of re-infection. 
     Ag-activated B cells may undergo differentiation into memory B cells or short and long-lived PCs. The differentiation into memory B cells may occur with or without T cell help and in a germinal center (GC)-dependent or independent manner. This results in memory B cells subsets that differ in their effector function and overall capacity for protection. 
     Sanz et al. (Sanz I, Wei C, Lee F E, Anolik J. Phenotypic and functional heterogeneity of human memory B cells.  Semin Immunol.  2008; 20(1):67-82) describe that memory B cells are more heterogeneous than previously thought. Despite initial descriptions of CD27 as a universal marker of human memory cells, memory populations were described that lack expression of CD27 and may be substantial in SLE and in some infections such as RSV. Additional heterogeneity of memory B cells can also be demonstrated on the basis of the expression of CD38, CD21, CD24, CD19, B220, FcRH4 and CD25. 
     Even though almost all cells in an individual contain the exact same complement of DNA code, higher organisms must impose and maintain different patterns of gene expression in the various types of tissue. Most gene regulation is transitory, depending on the current state of the cell and changes in external stimuli. Persistent regulation, on the other hand, is a primary role of epigenetics—heritable regulatory patterns that do not alter the basic genetic coding of the DNA. DNA methylation is the archetypical form of epigenetic regulation; it serves as the stable memory for cells and performs a crucial role in maintaining the long-term identity of various cell types. Recently, other forms of epigenetic regulation were discovered. In addition to the “fifth base” 5-methylcytosine (mC), a sixth (5-hydroxymethylcytosine, hmC), seventh (5-formylcytosine, fC) and eighth (5-carboxylcytosine, cC) can be found (Michael J. Booth et al. Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-Base Resolution Science 18 May 2012, Vol. 336 no. 6083 pp. 934-937). 
     The primary target of mentioned DNA modifications is the two-nucleotide sequence Cytosine-Guanine (a ‘CpG site’); within this context cytosine (C) can undergo a simple chemical modification to become formylated, methylated, hydroxymethylated, or carboxylated. In the human genome, the CG sequence is much rarer than expected, except in certain relatively dense clusters called ‘CpG islands’. CpG islands are frequently associated with gene promoters, and it has been estimated that more than half of the human genes have CpG islands (Antequera and Bird, Proc Natl Acad Sci USA 90: 11995-9, 1993). 
     Aberrant methylation of DNA is frequently associated with the transformation from healthy to cancerous cells. Among the observed effects are genome-wide hypomethylation, increased methylation of tumor suppressor genes, and hypomethylation of many oncogenes (reviewed, for example, by Jones and Laird, Nature Genetics 21:163-167, 1999; Esteller, Oncogene 21:5427-5440, 2002; and Laird, Nature Reviews/Cancer 3:253-266, 2003). Methylation profiles have been recognized to be tumor specific (i.e., changes in the methylation pattern of particular genes or even individual CpGs are diagnostic of particular tumor types), and there is now an extensive collection of diagnostic markers for bladder, breast, colon, esophagus, stomach, liver, lung, and prostate cancers (summarized, for example, by Laird, Nature Reviews/Cancer 3:253-266, 2003). 
     For one of the recently described modification of cytosine, 5-hydroxymethylation, the utility of oxidative bisulfite sequencing to map and quantify 5hmC at CpG islands was shown (Michael J. Booth et al. Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosine at Single-Base Resolution Science 18 May 2012, Vol. 336 no. 6083 pp. 934-937). High levels of 5hmC were found in CpG islands associated with transcriptional regulators and in long interspersed nuclear elements. It is suggested that these regions might undergo epigenetic reprogramming in embryonic stem cells. 
     WO 2012/162660 describes methods using DNA methylation arrays are provided for identifying a cell or mixture of cells and for quantification of alterations in distribution of cells in blood or in tissues, and for diagnosing, prognosing and treating disease conditions, particularly cancer. The methods use fresh and archival samples. 
     Zhang and Good-Jacobson (in: Epigenetic regulation of B cell fate and function during an immune response. Immunol Rev. 2019 March; 288(1):75-84) disclose that epigenetic modifications are crucial for ensuring that the appropriate genes are transcribed or repressed during B cell differentiation. Recent studies have illuminated the changes in DNA methylation and histone post-translational modifications that accompany the formation of germinal center and antibody-secreting cells during an immune response. In particular, the B cell subset-specific expression and function of DNA methyltransferases and histone-modifying complexes that mediate epigenome changes have begun to be unraveled. 
    
    
     In view of the above, it is an object of the present invention to provide an improved and in particular specific and robust method based on DNA-methylation analysis as a superior tool in order to more conveniently and reliably detect, identify, discriminate, and quantify memory B cells. 
     The present invention solves the above object by providing a method for identifying memory B cells in a sample, comprising analyzing the methylation status (bisulfite convertibility) of at least one CpG position in the mammalian (e.g. human) gene region for Chromobox protein homolog 6 (CBX6), wherein preferably said gene region as analyzed is positioned based on/according to SEQ ID No. 1, wherein further preferably said gene region as analyzed is positioned based on/according to SEQ ID No. 2, wherein a demethylation or lack of methylation of said gene region is indicative for a memory B cell, when compared to a non-memory B cell. 
     CBX6 (Chromobox 6 or Chromobox protein homolog 6) is a component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development. PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A ‘Lys-119’, rendering chromatin heritably changed in its expressibility. The gene for human CBX6 is found on chromosome 22, NC_000022.11. 
     Coradini et al. (in: Differential expression of genes involved in the epigenetic regulation of cell identity in normal human mammary cell commitment and differentiation.  Chin J Cancer.  2014; 33(10):501-510) disclose expression patterns of a panel of 369 genes known to be involved in the establishment and maintenance of epithelial cell identity and mammary gland remodeling in cell subpopulations isolated from normal human mammary tissue and selectively enriched in their content of bipotent progenitors, committed luminal progenitors, and differentiated myoepithelial or differentiated luminal cells. Differential expression of four genes involved in cell identity maintenance was found: CBX6 and PCGF2, encoding proteins belonging to the Polycomb group, and SMARCD3 and SMARCE1, encoding proteins belonging to the Trithorax group. 
     In the context of the present invention, the gene region shall comprise all of the genomic region relating to and encoding for CBX6. Thus, included are enhancer regions, promoter region(s), introns, exons, and non-coding regions (5′- and/or 3′-regions) that belong to CBX6. Preferred is thus a method according to the present invention, wherein the at least one CpG position is present in the 5′ region upstream from the transcription start, promoter region, the 5′ or 3′ untranslated regions, exon, intron, exon/intron border and/or in the 3′ region downstream of the transcriptional stop of the gene as analyzed. 
     The present invention is further based on the surprising identification of a region of the CBX6 gene by the inventors, as specific epigenetic marker, allowing the identification of memory B cells as well as the clinical routine application of said analysis. 
     In the context of the present invention, the genomic region of CBX6, in particular according to SEQ ID No. 1, more preferably SEQ ID NO. 2 (Amp 3005), allows for the identification of memory B cells. Surprisingly, the discriminatory pattern of bisulfite convertible and non-convertible cytosine is particularly and preferably exclusively limited to the genomic region according to SEQ ID No. 1 for memory B cells as shown using the amplicon according to SEQ ID No. 2. 
     The inventors could demonstrate that in the memory B cells the CpG motifs as disclosed are almost completely demethylated (i.e. to more than 70%, preferably 80%, preferably, more than 90% and most preferred more than 95%, even more than 98%), whereas the same motifs are nearly completely, and preferably completely methylated in non-memory B cells. This is referred to herein also as “demethylation” or “lack of methylation”. 
     The differential methylation of the CpG motifs within the aforementioned regions is a valuable tool to identify memory B cells, such as will be required/or at least of some value for identifying and quantifying said cells in autoimmune diseases, transplant rejections, cancer, allergy, primary and secondary immunodeficiencies, such as, for example, HIV infections and AIDS, Graft versus Host (GvH), hematologic malignancies, rheumatoid arthritis, multiple sclerosis, or a cytotoxic T cell related immune status in any envisionable diagnostic context. The assay allows measurement of memory B cells without purification or any staining procedures. 
     Another preferred aspect of the method according to the present invention then further comprises a quantification of the relative amount of memory B cells based on comparing relative amounts of said methylation frequency in the region as analyzed with relative amounts of the methylation frequency in a control gene, such as, for example, GAPDH. Said quantification is thus achieved based on the ratio of the bisulfite convertible DNA to non-convertible DNA in the genetic region of CBX6 (e.g. of SEQ ID No. 1) as described and analyzed herein. Most preferred is a quantification of the relative amount of memory B cells is based on an (preferably parallel or simultaneous) analysis of the relative amount of bisulfite convertible DNA of cell-specific region for CBX6, and of the relative amount of bisulfite convertible DNA of cell-unspecific genes (preferably designated “control genes” or “control regions”, such as, for example, the gene for GAPDH). 
     In a further preferred embodiment of the method according to the present invention, said analysis of bisulfite convertibility comprises amplification with at least one primer of suitable primer pairs that can be suitably designed based on SEQ ID No. 1, preferably oligomers according to any of SEQ ID No. 3 to 10. 
     In contrast to FACS and mRNA measurements, using the methods according to the present invention, the measurement(s) and analyses can be done independent of purification, storage—and to quite some extent—also to tissue quality. 
     Preferably, the amplification involves a polymerase enzyme, a PCR or chemical amplification reaction, or other amplification methods as known to the person of skill as described below, e.g. in the context of MSP, HeavyMethyl, Scorpion, MS-SNUPE, MethylLight, bisulfite sequencing, methyl specific restriction assays and/or digital PCR (see, for example Kristensen and Hansen PCR-Based Methods for Detecting Single-Locus DNA Methylation Biomarkers in Cancer Diagnostics, Prognostics, and Response to Treatment Clinical Chemistry 55:8 1471-1483 (2009)). 
     With the amplification, an amplicon of the CBX6 gene region is produced that is a particularly preferred “tool” for performing the method(s) according to the present invention. Consequently, oligomers according to any of SEQ ID No. 3 to 10 or an amplicon as amplified by a primer pair based on SEQ ID No. 3 and 4 or 5 and 6 or 8 and 9 as mentioned herein constitute preferred embodiments of the present invention. Thus, the sequences of SEQ ID No. 1 to 2 (and, if needed, the complementary sequences thereto) can be used to design primers for amplifications, i.e. serve as “beacons” in the sequence as relevant. Similarly, additional primers and probes can be designed based on the amplicon according to SEQ ID No. 1. Amplification can take place either in the genomic and/or bisulfite (i.e. “converted”) DNA sequence. 
     The person of skill will furthermore be able to select specific subsets of CpG positions in order to minimize the amount of sites to be analyzed, for example at least one of CpG position selected from a CpG position in an amplicon according to SEQ ID No. 1, and is preferably selected from the CpG positions 55, 91, 96, 115, 157, 171, 202, 240, 408, and 439 in the amplicon 3005 according to SEQ ID No. 2, and is more preferably selected from CpG positions 91, 157, 171, 202, 240, 408, and 439 in a fragment of the amplicon 3005 according to SEQ ID No. 2. Preferred are combinations of 3, 4, 5, 6, 7, 8, 9, or 10 positions, the analysis of which produces sufficient data and/or information in order to be informative in the context of the present invention. 
     The person of skill will furthermore be able to select specific subsets of CpG positions in order to minimize the amount of sites to be analyzed, for example at least one of CpG position 157, 171, 202, 240, 408, and 439 in the amplicon No. 3005 of the CBX6 specific bisulfite convertible region (SEQ ID No. 1), or all sites as present on the bisulfite convertible region according to SEQ ID No 1. One or more of positions 96, and/or 115 in AMP 3005 may be excluded. 
     In order to analyze the bisulfite convertibility of CpG positions, any known method to analyze DNA methylation can be used. In a preferred embodiment of the method according to the present invention, the analysis of the methylation status comprises a method selected from methylation specific enzymatic digests, bisulphite sequencing, analysis selected from promoter methylation, CpG island methylation, MSP, HeavyMethyl, MethyLight, Ms-SNuPE or other methods relying on a detection of amplified DNA. These methods are well known to the person of skill, and can be found in the respective literature. 
     In a preferred embodiment of the method according to the present invention, said method is suitable for routine application, for example on a DNA-chip. Based on the above information and the respective literature, the person of skill will be able to adjust the method as above to such settings. 
     In yet another preferred embodiment of the methods according to the present invention, said method is performed without a step of purifying and/or enriching said cells to be identified, preferably using whole blood and/or non-trypsinized tissue. 
     In another preferred embodiment of the method according to the present invention, the identification comprises a distinction of said memory B cells from all major peripheral blood cell types and/or non-blood cells, preferably, but not limited to, CD4+ T cells, memory CD4+ T cells, CD8+ T cells, CD15+ granulocytes, CD14+ monocytes, naive CD4+ T cells, CD56+NK-cells, naive CD8+ T cells, naive B cells, and other cell types derived from other organs than blood, in particular from naive B cells. 
     In yet another preferred embodiment of the method according to the present invention, the sample is selected from a mammalian body fluid, including human blood samples, or a tissue, organ or a sample of lymphocytes or a purified or separated fraction of such tissue, organ or lymphocytes or a cell type sample. Preferably, said mammal is a mouse, goat, dog, pig, cat, cow rat, monkey or human. The samples can be suitably pooled, if required. Preferably said cells are human cells. 
     Another preferred aspect of the method according to the present invention then further comprises the step of concluding on the immune status of said mammal based on said memory B cells. The memory B cells can be quantified and be used as a benchmark to relatively quantify further detailed subpopulations, or it can be used as a predictive and/or screening and/or diagnostic and/or prognostic and/or adverse events detecting factor, or it can be used to finally detect this population to determine the overall immune activity status. 
     In yet another preferred embodiment of the methods according to the present invention, the mammal suffers from or is likely to suffer from autoimmune diseases, transplant rejections, infection diseases, cancer, and/or allergy as but not limited to  Trypanosoma cruzi -infection, Malaria and HIV infection; Hematologic Malignancies as but not limited to chronic Myelogenous Leukemia, Multiple Myeloma, Non Hodgkin&#39;s Lymphoma, Hodgkin&#39;s Disease, chronic Lymphocytic Leukemia, Graft versus Host and Host versus Graft Disease, Mycosis fungoides, Extranodal T cell lymphoma, Cutaneous T cell lymphomas, Anaplastic large cell lymphoma, Angioimmunoblastic T cell lymphoma and other T-cell, B-cell and NK cell neoplasms, T cell deficiencies such as but not limited to lymphocytopenia, severe combined immunodeficiency (SCID), Omenn syndrome, Cartilage-hair hypoplasia, acquired immune deficiency syndrome (AIDS), and hereditary conditions such as DiGeorge syndrome (DGS), chromosomal breakage syndromes (CBSs), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren&#39;s syndrome, systemic sclerosis, dermatomyositis, primary biliary cirrhosis, primary sclerosing cholangitis, ulcerative colitis, Crohn&#39;s disease, psoriasis, vitiligo, bullous pemphigoid, alopecia areata, idiopathic dilated cardiomyopathy, type 1 diabetes mellitus, Graves&#39; disease, Hashimoto&#39;s thyroiditis, myasthenia gravis, IgA nephropathy, membranous nephropathy, and pernicious anemia; and B-cell and T-cell combined disorders such as but not limited to ataxia telangiectasia (AT) and Wiskott-Aldrich syndrome (WAS); and carcinomas such as but not limited to breast cancer, colorectal cancer, gastric cancer, pancreatic cancer, hepatocellular carcinoma, cholangiocarcinoma, melanoma, and head and neck cancer. 
     Another preferred aspect of the method according to the present invention then relates to a method as above, further comprising measuring and/or monitoring the amount of memory B cells in response to chemical and/or biological substances that are provided to said mammal, i.e. in response to a treatment of said patient. Said method comprises the steps as above, and comparing said relative amount of said cells as identified to a sample taken earlier or in parallel from the same mammal, and/or to a control sample. Based on the results as provided by the method(s) of the invention, the attending physician will be able to conclude on the immune status of the patient, and adjust a treatment of the underlying disease accordingly. 
     Preferably, said method is performed without a step of purifying and/or enriching cells, preferably in whole blood and/or non-trypsinized tissue, or any other biological sample potentially containing said memory B cells as e.g. a sample for cell transfer into a patient. 
     Another preferred aspect of the method according to the present invention then relates to a method as above, further comprising formulating said memory B cells as identified for transplantation into a patient. Pharmaceutical preparations for these purposes and methods for their production are performed according to methods known in the art of transplantation medicine. 
     Another preferred aspect of the method according to the present invention then further then relates to a method for treating a condition or disease in a mammal, in particular in a human, comprising a method according to the invention as above, and the step of transplanting memory B cells as identified (e.g. in an aliquod taken from the sample) and isolated/multiplied in cell culture into a patient. Pharmaceutical preparations for these purposes and methods for their production are performed according to methods known in the art of transplantation medicine. The transplant can be autologous or allogenic. 
     Another preferred aspect of the method according to the present invention then further then relates to a method for treating and/or preventing a condition or disease in a mammal, in particular in a human, comprising a method according to the invention as above including a suitable treatment for said condition or disease comprising providing chemical and/or biological substances as above, and adjusting said treatment of the underlying disease or condition based on the results as provided by the method(s) of the invention. This may comprise the step of concluding on the immune status of said mammal based on said memory B cells. The memory B cells can be quantified and be used as a benchmark to relatively quantify further detailed subpopulations, or it can be used as a predictive and/or screening and/or diagnostic and/or prognostic and/or adverse events detecting factor, or it can be used to finally detect this population to determine the overall immune activity status. This basis allows for adjusting said treatment, if necessary. Such adjustments may comprise the step of transplanting memory B cells as identified and isolated/multiplied in cell culture into a patient as above, and/or providing additional chemical and/or biological substances for adjusting said treatment and/or prevention. 
     One particular example is a method for treating and/or preventing a condition or disease in a mammal, in particular in a human, wherein first a vaccine is provided to said mammal. Respective vaccines and vaccination strategies are known, generally, vaccines contain the same germs (sometimes inactivated) that cause disease, or immunogenic parts thereof, optionally with suitable carriers and adjuvants. The success of a vaccine is dependent on the generation and maintenance of immunological memory, and the immune system can remember previously encountered pathogens, and memory B cells are critical in secondary responses to infection. Therefore, the method then comprises measuring and/or monitoring the amount of memory B cells in response to said vaccination(s) that is/are provided to said mammal. In case of an insufficient number of memory B cells, said treatment (here: vaccination) is adjusted, i.e. preferably a booster shot is given. The method may be repeated until sufficient immune cells (i.e. a substantial population of memory B cells) can be detected. 
     Another particular example is a method for generating immunity against an antigen comprising the method as above comprising providing at least one antigen as a vaccine, and detecting a sufficient immunity based on the population of memory B cells as identified in response to said at least one antigen as provided as said vaccine. 
     Treatment and/or prevention shall herein relate to the curing, prevention or alleviation of a disorder or malfunction of the body, i.e. bringing a body back to its healthy state. 
     Pharmaceutical preparations for these purposes and methods for their production are performed according to methods known in the art of a treatment using chemical and/or biological substances or transplantation medicine. Again, the transplant can be autologous or allogenic. 
     Another preferred aspect of the method according to the present invention relates to an oligomer according to any of SEQ ID No. 3 to 10, or an amplicon according to SEQ ID No. 2. 
     Yet another preferred aspect of the present invention then relates to a kit for identifying, quantifying, and/or monitoring memory B cells in a mammal based on the analysis of the bisulfite accessibility of CpG positions in the gene region for CBX6, comprising components for performing a method according to invention as described herein, in particular a kit comprising a) a bisulfite reagent, and b) materials for the analysis of the methylation status of CpG positions selected from the CpG positions in the region according to SEQ ID NO: 1 or 2, such as an oligomer selected from the sequences according to SEQ ID No. 3 to 10, or an amplicon as amplified by a primer pair based on SEQ ID No. 3 and 4 or 5 and 6 or 8 or a primer pair based on SEQ ID No. 3 and 4 or 5 and 6 or 8, respectively. 
     The present invention also encompasses the use of oligomers or amplicon or a kit according to the present invention for identifying and/or for monitoring memory B cells in a mammal as described herein. 
     As mentioned above, recently three new cytosine modifications were discovered. Therefore, it is expected that future scientific findings will correct epigenetic patterns of modification described in the past. These past patterns of cytosine modification encompass bisulfite convertible (non-methylated, non-modified) and non-convertible (methylated, modified) cytosine. Both termini need to be corrected, as described. According to the novel scientific findings (i) non-bisulfite convertible cytosine encompasses 5-methylcytosine (mC) and 5-hydroxymethylcytosine (hmC), and (ii) bisulfite convertible (i.e. the “bisulfite convertibility”) cytosine encompasses 5-formylcytosine (fC), 5-carboxylcytosine (cC), as well as non-modified cytosine. 
     Additionally, past inventions are based on (i) the ratio of bisulfite convertible cytosine to whole amount of chromatin (cell-type independent, 100% bisulfite convertible DNA locus) or (ii) on the ratio of bisulfite convertible cytosine (fC, cC, non-modified cytosine) to non-bisulfite convertible cytosine (hmC and mC). These ratios characterize cell type, cell differentiation, cell stage as well as pathological cell stages. Therefore, new techniques will result in novel, more specific ratios and might supplement current cell specific, cell state specific as well as pathological patterns of epigenetic modifications and therefore, define potential novel biomarkers. Novel ratios to be discovered as biomarkers can be defined as: 
       Biomarker Ratio= a/b    
     a=Σ(C and/or mC and/or hmC and/or fC and/or cC) 
     b=Σ(C and/or mC and/or hmC and/or fC and/or cC), 
     whereby a and b differs from each other by one to four kinds of modifications. Discovery of novel DNA modifications will enlarge this enumeration. 
     For the purpose of definition for the present application, “epigenetic modifications” in the DNA sequence is referred to by the terminology of (i) bisulfite convertible cytosine (5-formylcytosine, (fC) and/or 5-carboxylcytosine (cC)) and (ii) non-bisulfite convertible cytosine ((including 5-methylcytosine (mC), 5-hydroxymethylcytosine, (hmC)). As both kinds of methylation, mC and hmC, are not bisulfite convertible, it is not possible to distinguish between these two. Likewise, fC, cC as well as non-modified cytosine are bisulfite convertible and can also not be distinguished from each other as well. The term “methylated” DNA encompasses mC as well as hmC. The term “non-methylated” DNA encompasses fC, cC, and non-modified DNA. It is expected that novel variants of DNA modifications will be discovered in future. Each type of modification will be either bisulfite convertible or not. However, since the present method reliably distinguishes between the two groups, these novel modifications will also be usable as markers. 
     Furthermore, apart from the modifications of DNA, also histones undergo posttranslational modifications that alter their interaction with DNA and nuclear proteins. Modifications include methylation, acetylation, phosphorylation, ubiquitination, sumoylation, citrullination, and ADP-ribosylation. The core of the histones H2A, H2B, and H3 can also be modified. Histone modifications act in diverse biological processes such as gene regulation, DNA repair, chromosome condensation (mitosis) and spermatogenesis (meiosis). Also for these modifications a specific pattern of modification is specific for different cell types, cell stages, differentiation status and such a pattern can be analyzed for bisulfite convertibility or similar methods in order to identify certain cells and cell stages. The present invention also encompasses a use of these modifications. 
     In summary, using the CBX6 genetic region and in particular the amplicon as described herein as a marker, the inventors very specifically identified, quantified and particularly differentiated memory B cells, and in their relation to other cell types in a sample, for example to other blood cells. 
     The invention will now be further described in the following examples and with reference to the accompanying figures and the sequence listing, without being limited thereto. For the purposes of the present invention, all references as cited herein are incorporated by reference in their entireties. 
       FIG.  1    shows the analysis of CpG sites on amplicon No. 3005 (SEQ ID No. 2) according to the invention. The columns in the table correspond to the CpG positions in the amplicon as analyzed (e.g. CpG 1, 2, etc.) with the positions indicated (AMP3005:55 corresponding to CpG at position 55 of Amplicon 3005 according to SEQ ID No. 2, . . . etc.), and the rows correspond to the cell types as analyzed. 
       FIG.  2    shows the genomic region of the amplicon according to the present invention (SEQ ID No. 1, the amplicon sequence (SEQ ID NO. 2) is underlined. 
       FIG.  3    shows the genomic sequence of the amplicon according to the present invention (SEQ ID No. 2), the relevant CpG positions are bold and underlined. 
     SEQ ID No. 1 shows the sequence of the genomic region (genomic sequence with the Ensembl-coordinates 22:38860000:38875000:1) of the amplicon No. 3005 according to the present invention (see also  FIG.  2   ).  Homo sapiens  chromobox 6 (CBX6), transcript variant 1, mRNA, NCBI Reference Sequence: NM_014292.5. 
     SEQ ID No. 2 shows the genomic sequence of amplicon No. 3005. 
     SEQ ID Nos. 3 to 10 show the sequences of specific oligomers (primers and probes) according to the present invention. 
     EXAMPLES 
     Example 1 
     In order to identify memory B cells, qPCR was performed on bisulphite converted samples stemming from the human genomic region according to the sequence SEQ ID No. 1 (see  FIG.  2   ), in particular the region AMP3005 (underlined, and see  FIG.  3   ). 
     For the actual epigenetic profiling of the amplicon region in blood cell subtypes, the immune cell populations as analyzed were as shown in  FIG.  1   . 
     The bisulfite-converted target-regions of preferred qPCR-assay-system as developed were: 
     Oligonucleotides for Bisulfite Sequencing (5′-3′) 
     
       
         
           
               
               
            
               
                   
                 Forward Primer- 
               
               
                   
                 (SEQ ID NO: 3) 
               
               
                   
                 TTAGATTGTAATTTTTGTTTGGTAA 
               
               
                   
                   
               
               
                   
                 Reverse Primer- 
               
               
                   
                 (SEQ ID NO: 4) 
               
               
                   
                 AATTTCTTACCCCCTTCTATTC 
               
            
           
         
       
     
     Oligonucleotides of qPCR Assay (TpG Variant i.e., demethylation-specific; 5′-3′) 
     
       
         
           
               
               
            
               
                   
                 Forward Primer- 
               
               
                   
                 (SEQ ID NO: 5) 
               
               
                   
                 GGAAAGTAGTAAGGGTGGAT 
               
               
                   
                   
               
               
                   
                 Reverse Primer- 
               
               
                   
                 (SEQ ID NO: 6) 
               
               
                   
                 CCCTCTCTAATACCCCCA 
               
               
                   
                   
               
               
                   
                 Probe- 
               
               
                   
                 (SEQ ID NO: 7) 
               
               
                   
                 TTGATTTGTGTAAGTGTGTGGGAGGTGG 
               
            
           
         
       
     
     Oligonucleotides of qPCR Assay (CpG Variant i.e., methylation-specific; 5′-3′) 
     
       
         
           
               
               
            
               
                   
                 Forward Primer- 
               
               
                   
                 (SEQ ID NO: 8) 
               
               
                   
                 GGAAAGTAGTAAGGGTGGAC 
               
               
                   
                   
               
               
                   
                 Reverse Primer- 
               
               
                   
                 (SEQ ID NO: 9) 
               
               
                   
                 CCCTCTCTAATACCCCCG 
               
               
                   
                   
               
               
                   
                 Probe- 
               
               
                   
                 (SEQ ID NO: 10) 
               
               
                   
                 TCGATTCGTGTAAGTGTGTGGGAGGCGG 
               
            
           
         
       
     
     The cell type specificity (FACS-sorted immune cell preparations with memBLC qPCR) was found as follows (table 1): 
     
       
         
           
               
               
               
             
               
                   
               
               
                   
                   
                 Demethylation 
               
               
                 Cell type 
                 Description 
                 (%) 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 Memory B cells 
                 CD3−/CD20+/IgD−/CD27+ 
                 ≥99.9 
               
               
                 Memory B cells 
                 CD19+/IgD−/CD27+ 
                 ≥99.9 
               
               
                 CD19+ B cells 
                 CD19+ 
                 22.61 
               
               
                 Naïve B cells 
                 CD3−/CD20+/IgD+/CD27− 
                 5.61 
               
               
                 Naïve B cells 
                 CD19+/IgD+/CD27− 
                 1.99 
               
               
                 Granulocytes 
                 CD15++ 
                 0.23 
               
               
                 T Helper cells 
                 CD3+CD4+ 
                 2.17 
               
               
                 T Helper cells 
                 CD3+/CD8−/CD4+ 
                 2.53 
               
               
                 Cytotoxic T cells 
                 CD3+/CD8+/CD4− 
                 1.65 
               
               
                 Cytotoxic T cells 
                 CD3+/CD8+/ 
                 1.22 
               
               
                 CD56+ NK cells 
                 CD3−/CD56+/CD16+ 
                 0.17 
               
               
                 Monocytes 
                 CD14+ 
                 0.20